Marinomed Biotech AG (VIE:MARI)
Austria · Delayed Price · Currency is EUR 4.000
0.00 (0.00%)
Sep 25, 2026, 7:53 AM CET
Marinomed Biotech AG Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8 | 35 | 27 | 44 | 85 | 130 | |
Market Cap Growth | -78.05% | 31.75% | -39.87% | -47.78% | -34.78% | -25.67% |
Enterprise Value | 19 | 45 | 47 | 63 | 98 | 140 |
Last Close Price | 4.00 | 19.03 | 14.95 | 29.10 | 56.20 | 87.69 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 0.41 | 1.95 | - | - | - | - |
Forward PE | - | 3.41 | 11.11 | 17.72 | 17.72 | 15.78 |
PS Ratio | 1.00 | 4.42 | 5.57 | 4.72 | 7.23 | 11.20 |
PB Ratio | - | -4.99 | -1.02 | -3.52 | -20.43 | 680.53 |
P/TBV Ratio | - | - | - | - | - | 8983.04 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.34 | 5.60 | 9.72 | 6.70 | 8.38 | 12.06 |
EV/EBITDA Ratio | - | 928.37 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | -1.64 | -1.64 | -1.12 | -1.71 | -5.44 | 82.54 |
Debt / EBITDA Ratio | 240.74 | 240.74 | - | - | - | - |
Net Debt / Equity Ratio | -1.51 | -1.51 | -1.05 | -1.51 | -3.48 | 52.23 |
Net Debt / EBITDA Ratio | 220.92 | 220.92 | -4.20 | -3.42 | -2.95 | -1.89 |
Net Debt / FCF Ratio | -9.64 | -9.64 | -11.49 | -5.14 | -2.66 | -1.73 |
Asset Turnover | 1.13 | 1.13 | 0.47 | 0.54 | 0.54 | 0.52 |
Inventory Turnover | 5.27 | 5.27 | 5.28 | 6.59 | 7.26 | 10.68 |
Quick Ratio | 0.22 | 0.22 | 0.08 | 0.55 | 1.90 | 1.77 |
Current Ratio | 0.25 | 0.25 | 0.10 | 0.66 | 2.40 | 2.14 |
Return on Equity (ROE) | - | - | - | - | - | -212.34% |
Return on Assets (ROA) | -2.33% | -2.33% | -42.45% | -21.70% | -15.14% | -15.78% |
Return on Invested Capital (ROIC) | -147.00% | - | - | -63.08% | -39.85% | -59.09% |
Return on Capital Employed (ROCE) | -147.90% | -147.90% | 29.90% | -219.80% | -32.40% | -36.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 225.34% | 51.27% | -57.79% | -14.35% | -7.53% | -4.52% |
FCF Yield | -13.76% | -3.13% | -9.00% | -8.34% | -6.39% | -4.44% |
Buyback Yield / Dilution | -3.46% | -3.46% | -17.14% | -1.29% | -1.56% | -0.31% |